NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer s & Parkinson s Drug Development Summit Seite 1
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer s & Parkinson s Drug Development Summit
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.